Immunologic features of chronic granulomatous mucocutaneous candidiasis before and after treatment with transfer factor.
We report the acquisition of skin test sensitivity to Candida albicans antigen and the ability to produce leukocyte migration inhibition factor (MIF) by a Candida-negative patient with chronic granulomatous mucocutaneous candidiasis after treatment with dialyzable transfer factor (TFd). The TFd was acquired from Candida-positive healthy donors. Three of seven attempts to transfer Candida skin test sensitivity were successful, and the acquired skin reactivity lasted for 12 to 21 days. The acquisition of cellular immunity to Candida was demonstrated in vitro by production of leukocyte MIF. No Candida-induced lymphocyte transformation was observed before or after TFd injection. The TFd did not cause Candida-induced blast transformation when added directly to cultures of lymphocytes from the patient. Pain, tenderness, redness, and edema were observed around the Candida granulomas on each occasion when the skin test to Candida became positive. Two weeks after TDd injection, the proliferative response of peripheral blood lymphocytes increased, as measured by incorporation of tritiated thymidine into lymphocytes within the first hour of in vitro incubation.
D002179:Candidiasis, Cutaneous / Q000276:immunology / Q000628:therapy*; D002180:Candidiasis, Oral / Q000276:immunology / Q000628:therapy*; D002648:Child; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor